Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

Background: Patients with relapsing–remitting multiple sclerosis (RRMS) may experience breakthrough disease despite effective interferon beta (IFNβ) therapy. Fludarabine (FLU) is a chemotherapeutic agent used in lymphoproliferative disorders that may be synergistic when combined with immunomodulator...

Full description

Bibliographic Details
Main Authors:	Steven J. Greenberg, Robert Zivadinov, Peterkin Lee-Kwen, Jitendra Sharma, Margaret Planter, Margaret Umhauer, Norman Glenister, Rohit Bakshi
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-03-01
Series:	Therapeutic Advances in Neurological Disorders
Online Access:	https://doi.org/10.1177/1756285615626049

Similar Items

Adrenocorticotropic hormone methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial
by: Regina Berkovich, et al.
Published: (2017-01-01)

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
by: Barletta Valeria, et al.
Published: (2011-02-01)

[18F]-Fludarabine for Hematological Malignancies
by: Louisa Barré, et al.
Published: (2019-04-01)

New Insights into Molecular Mechanisms of Fludarabine
by: Bulgar, Alina D.
Published: (2008)

Beta-interferons in multiple sclerosis
by: Aggarwal Sourabh, et al.
Published: (2010-01-01)

Fludarabin v terapii razlichnykhvariantov nekhodzhkinskikh limfom
by: S S Bessmel'tsev, et al.
Published: (2011-12-01)

Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies
by: Donald Pasquale
Published: (2014-08-01)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
by: Ann Janssens, et al.
Published: (2009-10-01)

Fludarabine-induced bradycardia in a patient with refractory leukemia
by: Chung-Lo Woei, et al.
Published: (2010-01-01)

Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients
by: Amir Ali Hamidieh, et al.
Published: (2011-07-01)

Neutralising antibodies to interferon beta in multiple sclerosis
by: Farrell, R. A.
Published: (2010)

Analyse der Gesundheits-assoziierten Lebensqualität bei jüngeren Patienten mit chronisch lymphatischer Leukämie unter Behandlung mit Fludarabin versus Fludarabin / Cyclophosphamid
by: Obwandner, Tanja
Published: (2006)

Primenenie preparata Vero-Fludarabin v terapii limfoproliferativnykh zabolevaniy
by: A B Fedorov, et al.
Published: (2007-12-01)

Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.
by: May Shawi, et al.
Published: (2013-01-01)

Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
by: S Walker, et al.
Published: (2009-06-01)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
by: Renata Oliveira Costa, et al.
Published: (2012-07-01)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
by: Lupini Laura, et al.
Published: (2010-05-01)

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.
by: Tamara Castillo-Trivino, et al.
Published: (2011-01-01)

Breakthroughs in Photonics 2012: Breakthroughs in Filamentation
by: H. M. Milchberg, et al.
Published: (2013-01-01)

[Pegylation and interferons in multiple sclerosis]
by: Diego Centonze, et al.
Published: (2016-07-01)

[18F] Fludarabine pour l'imagerie TEP des lymphomes
by: Hovhannisyan, Narinée
Published: (2018)

[18F]Fludarabine-PET in a murine model of multiple myeloma.
by: Narinée Hovhannisyan, et al.
Published: (2017-01-01)

Recurrent Acute Pulmonary Toxicity and Respiratory Failure Associated with Fludarabine Monophosphate
by: Corey Cutler, et al.
Published: (1997-01-01)

The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination
by: Volker Limmroth, et al.
Published: (2011-09-01)

THE INFLUENCE OF NEUTRALIZING ANTIBODIES TO INTERFERON-BETA ON PROGRESSION OF MULTIPLE SCLEROSIS
by: V. Yu. Lizhdvoy, et al.
Published: (2016-07-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
by: Masoud Mohammad Malekzadeh, et al.
Published: (2020-06-01)

A cost-utility analysis of interferon beta for multiple sclerosis.
by: Parkin, et al.
Published: (1998-01-01)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
by: S. Jeannin, et al.
Published: (2011-01-01)

Immunopharmacological aspects of methylprednisolone and interferon-beta therapies in multiple sclerosis
by: Boylan, M. T.
Published: (2002)

Effectiveness and safety of interferon α2a as an add-on treatment for refractory Behçet’s uveitis
by: Jing Shi, et al.
Published: (2019-05-01)

Quantification and characterization of anti-interferon beta antibodies in multiple sclerosis patients undergoing interferon beta-1b therapy
by: Gibbs, Ebrima
Published: (2009)

Quantification and characterization of anti-interferon beta antibodies in multiple sclerosis patients undergoing interferon beta-1b therapy
by: Gibbs, Ebrima
Published: (2009)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

The first experience with fludarabine used to treat a patient with refractory Wegener's granulomatosis
by: Vadim Romanovich Gorodetsky, et al.
Published: (2012-04-01)

Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphOCYtic leukemia
by: Tamara Pavlovna Zagoskina, et al.
Published: (2010-03-01)

Fludarabine Treatment of Patient with Chronic Lymphocytic Leukemia Induces a Digital Ischemia
by: Utku Erdem Soyaltin, et al.
Published: (2016-01-01)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
by: Marco Montillo, et al.
Published: (2008-03-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

In Situ Evaluation of Fludarabine-DNA Interaction Using a DNA-Electrochemical Biosensor
by: H. Eda Satana, et al.
Published: (2011-01-01)

Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells.
by: Lucie Lorkova, et al.
Published: (2015-01-01)